Olanzapina w formie tabletek rozpuszczających się w jamie ustnej: nowe możliwości terapeutyczne Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2011
Słowa kluczowe:
olanzapina, tabletki rozpuszczające się w jamie ustnej, masa ciała, współpraca z pacjentem
##plugins.themes.bootstrap3.article.main##
Abstrakt
Olanzapina należy do bezwzględnie najskuteczniejszych neuroleptyków. Nowe, długoterminowe badania pokazują również, że umożliwia pacjentom względnie najdłuższe okresy przeżycia. Z drugiej strony, podczas leczenia olanzapiną u części pacjentów dochodzi do znacznego wzrostu masy ciała. Ryzyko to może być ograniczone przy zastosowaniu specjalnej postaci olanzapiny – tabletek rozpuszczających się w jamie ustnej. Forma ta poprawia także współpracę z pacjentami podczas leczenia.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Łoza , B. (2011). Olanzapina w formie tabletek rozpuszczających się w jamie ustnej: nowe możliwości terapeutyczne . Medycyna Faktów , 4(1(10), 75-80. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2553
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Lieberman J.A., Stroup T.S., McEvoy J.P. et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
2. Kahn R.S., Fleischhacker W.W., Boter H. et al.: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008; 371: 1085-1097.
3. Jones P.B., Barnes T.R., Davies L. et al.: Randomized controlled trial of the effect on Quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087.
4. Karagianis J., Novick D., Pecenak J., Haro J.M., Dossenbach M., Treuer T., Montgomery W., Walton R., Lowry A.J.: Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009; 63: 1578-1588.
5. FDA, Food and Drug Administration [online].
6. Leucht S., Corves C., Arbter D. et al.: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31-41.
7. Leucht S., Komossa K., Rummel-Kluge C. et al.: A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. Am J Psychiatry 2009; 166: 152-163.
8. Tiihonen J., Lönnqvist J., Wahlbeck K. et al.: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374(9690): 620-627.
9. De Haan L., Van Amelsvoort T., Rosien K., Linszen D.: Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004; 175: 389-390.
10. Maayan L., Vakhrusheva J., Correll C.U.: Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systemic review and meta-analysis. Neuropsychopharmacology 2010; 35: 1520-1530.
11. Arranz B., San L., Duenas R.M., Centeno M., Ramirez N., Salavert J., del Moral E.: Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Human Psychopharmacology 2007; 22: 11-15.
12. Crocq M.A., Guillon M.S., Bailey P.E., Provost D.: Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. European Psychiatry 2007; 22: 453-454.
13. Chawla B., Luxton-Andrew H.: Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Human Psychopharmacology 2008; 23: 211-216.
14. Karagianis J., Hoffmann V.P., Arranz B., Treuer T., Maguire G.A., De Haan L., Chawla B.: Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Human Psychopharmacology 2008; 23: 275-281.
15. Karagianis J., Grossman L., Lee B., Monga N., de Haan L., Maguire G., Milev R., Hoffmann V.P.: A 16-week randomized double-blind, double dummy trial of sublingually disintegrating olanzapine vs. Standard olanzapine tablets in patients who gained weight during olanzapine. Schizophrenia Research 2008; 102/1-3(supl. 2): 238(p.542).
16. San L., Casillas M., Ciudad A., Gilaberte I.: Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neuroscience & Therapeutics 2008; 14: 208-214.
17. Ciorabai E.M., Oyffe I., Dilbaz N., Lozano S., Ruschel S., Salburg J., Dyachkova Y., Treuer T.: Patients preference of olanzapine orodispersible tablet compared with olanzapine classic oral tablet in a multinational, randomized, crossover study. European Psychiatry 2008; 23(supl. 2): 150-151.
18. Kinon B.J., Hill A.L., Liu H., Kollack-Walker S.: Olanzapine orally disintegrating tablets in the treatment of acutely ill, non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 2003; 6: 97-102.
19. Czekalla J., Wagner T., Schacht A., Kluge M., Kinon B.: Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Preferences and Adherence 2007; 1: 19-27.
20. Dardennes R., Chartier F., Heurtebize N., Olivier V., Perrin E.: Naturalistic use of the orally disintegrating tablet formulation of olanzapine in acute schizophrenic patients: An observational prospective study. Int J Neuropsychopharmacol 2004; 7(supl. 2): P01.389.
21. Bergstrom R.F., Mitchell M., Witcher J., Huorston J.P., Hill A.L., Taylor C.C., Liu-Seifert H., Jones B.: Rapid onset of absorption with olanzapine orally disintegrating tablets. Schizophrenia Research 2004; 67(supl. 1): 160.
22. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., Tollefson G.D.: Factors influencing acute weight gain in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry 2001; 62: 231-238.
23. Zipursky R.B., Gu H., Green A.I. et al.: Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187: 537-543.
24. Łoza B., Grzesiewska J., Wójcik M.: Przypadek wczesnej schizofrenii leczonej w warunkach politerapii olanzapiną i ziprasidonem. Neuropsychiatria. Przegląd Kliniczny 2009; 1(1): 38-40.
2. Kahn R.S., Fleischhacker W.W., Boter H. et al.: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008; 371: 1085-1097.
3. Jones P.B., Barnes T.R., Davies L. et al.: Randomized controlled trial of the effect on Quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087.
4. Karagianis J., Novick D., Pecenak J., Haro J.M., Dossenbach M., Treuer T., Montgomery W., Walton R., Lowry A.J.: Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009; 63: 1578-1588.
5. FDA, Food and Drug Administration [online].
6. Leucht S., Corves C., Arbter D. et al.: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31-41.
7. Leucht S., Komossa K., Rummel-Kluge C. et al.: A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. Am J Psychiatry 2009; 166: 152-163.
8. Tiihonen J., Lönnqvist J., Wahlbeck K. et al.: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374(9690): 620-627.
9. De Haan L., Van Amelsvoort T., Rosien K., Linszen D.: Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004; 175: 389-390.
10. Maayan L., Vakhrusheva J., Correll C.U.: Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systemic review and meta-analysis. Neuropsychopharmacology 2010; 35: 1520-1530.
11. Arranz B., San L., Duenas R.M., Centeno M., Ramirez N., Salavert J., del Moral E.: Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Human Psychopharmacology 2007; 22: 11-15.
12. Crocq M.A., Guillon M.S., Bailey P.E., Provost D.: Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. European Psychiatry 2007; 22: 453-454.
13. Chawla B., Luxton-Andrew H.: Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Human Psychopharmacology 2008; 23: 211-216.
14. Karagianis J., Hoffmann V.P., Arranz B., Treuer T., Maguire G.A., De Haan L., Chawla B.: Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Human Psychopharmacology 2008; 23: 275-281.
15. Karagianis J., Grossman L., Lee B., Monga N., de Haan L., Maguire G., Milev R., Hoffmann V.P.: A 16-week randomized double-blind, double dummy trial of sublingually disintegrating olanzapine vs. Standard olanzapine tablets in patients who gained weight during olanzapine. Schizophrenia Research 2008; 102/1-3(supl. 2): 238(p.542).
16. San L., Casillas M., Ciudad A., Gilaberte I.: Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neuroscience & Therapeutics 2008; 14: 208-214.
17. Ciorabai E.M., Oyffe I., Dilbaz N., Lozano S., Ruschel S., Salburg J., Dyachkova Y., Treuer T.: Patients preference of olanzapine orodispersible tablet compared with olanzapine classic oral tablet in a multinational, randomized, crossover study. European Psychiatry 2008; 23(supl. 2): 150-151.
18. Kinon B.J., Hill A.L., Liu H., Kollack-Walker S.: Olanzapine orally disintegrating tablets in the treatment of acutely ill, non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 2003; 6: 97-102.
19. Czekalla J., Wagner T., Schacht A., Kluge M., Kinon B.: Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Preferences and Adherence 2007; 1: 19-27.
20. Dardennes R., Chartier F., Heurtebize N., Olivier V., Perrin E.: Naturalistic use of the orally disintegrating tablet formulation of olanzapine in acute schizophrenic patients: An observational prospective study. Int J Neuropsychopharmacol 2004; 7(supl. 2): P01.389.
21. Bergstrom R.F., Mitchell M., Witcher J., Huorston J.P., Hill A.L., Taylor C.C., Liu-Seifert H., Jones B.: Rapid onset of absorption with olanzapine orally disintegrating tablets. Schizophrenia Research 2004; 67(supl. 1): 160.
22. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., Tollefson G.D.: Factors influencing acute weight gain in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry 2001; 62: 231-238.
23. Zipursky R.B., Gu H., Green A.I. et al.: Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187: 537-543.
24. Łoza B., Grzesiewska J., Wójcik M.: Przypadek wczesnej schizofrenii leczonej w warunkach politerapii olanzapiną i ziprasidonem. Neuropsychiatria. Przegląd Kliniczny 2009; 1(1): 38-40.